Clinical and radiological features of brain neurotoxicity caused by antitumor and immunosuppressant treatments

Alessandra Erbetta, Andrea Salmaggi, Angelo Sghirlanzoni, Antonio Silvani, Paolo Potepan, Andrea Botturi, Elisa Ciceri, Maria Grazia Bruzzone

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Antitumor and immunosuppressant treatment-related neurotoxicity can determine nonspecific clinical syndromes. Exclusion of other possible causes, among which tumor progression, appearance of paraneoplastic disease, renal or hepatic failure, diabetes or hypertension, is relevant. We report clinical and neuroradiological features in five patients with neurotoxic syndromes due to chemotherapy/radiotherapy or immunosuppression in the context of neoplastic disease/organ transplantation. Acute neurological syndrome developed in three patients after methotrexate (MTX), cyclosporine A, and L-asparaginase therapy, respectively. MRI showed posterior reversible encephalopathy in two cases and venous thrombosis with intraparenchymal hematoma in the third patient. Late onset clinical syndrome occurred in the last two patients, treated with MTX or radiation therapy for breast cancer metastasis and pituitary adenoma. Neuroimaging showed brain diffuse abnormalities. Patients affected by tumors suffer from increased risk for treatment-related toxicities. Appearance or worsening of neurological signs and symptoms challenge the clinician to discriminate between CNS involvement by the tumor, toxicity of drugs, parane-oplastic disease and infections. MRI has a key role in differential diagnosis. Close interaction between the neurologist, the oncologist and the neuroradiologist leads to the optimal management of patients.

Original languageEnglish
Pages (from-to)131-137
Number of pages7
JournalNeurological Sciences
Volume29
Issue number3
DOIs
Publication statusPublished - Jun 2008

Fingerprint

Immunosuppressive Agents
Brain
Pituitary Neoplasms
Methotrexate
Radiotherapy
Therapeutics
Asparaginase
Neoplasms
Liver Failure
Brain Diseases
Organ Transplantation
Drug-Related Side Effects and Adverse Reactions
Neuroimaging
Venous Thrombosis
Hematoma
Immunosuppression
Cyclosporine
Signs and Symptoms
Renal Insufficiency
Differential Diagnosis

Keywords

  • Mineralizing angiopathy
  • Neurotoxicity
  • Posterior reversible encephalopathy

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Clinical and radiological features of brain neurotoxicity caused by antitumor and immunosuppressant treatments. / Erbetta, Alessandra; Salmaggi, Andrea; Sghirlanzoni, Angelo; Silvani, Antonio; Potepan, Paolo; Botturi, Andrea; Ciceri, Elisa; Bruzzone, Maria Grazia.

In: Neurological Sciences, Vol. 29, No. 3, 06.2008, p. 131-137.

Research output: Contribution to journalArticle

@article{db36e53f8a3041e789486a6dbe404b0b,
title = "Clinical and radiological features of brain neurotoxicity caused by antitumor and immunosuppressant treatments",
abstract = "Antitumor and immunosuppressant treatment-related neurotoxicity can determine nonspecific clinical syndromes. Exclusion of other possible causes, among which tumor progression, appearance of paraneoplastic disease, renal or hepatic failure, diabetes or hypertension, is relevant. We report clinical and neuroradiological features in five patients with neurotoxic syndromes due to chemotherapy/radiotherapy or immunosuppression in the context of neoplastic disease/organ transplantation. Acute neurological syndrome developed in three patients after methotrexate (MTX), cyclosporine A, and L-asparaginase therapy, respectively. MRI showed posterior reversible encephalopathy in two cases and venous thrombosis with intraparenchymal hematoma in the third patient. Late onset clinical syndrome occurred in the last two patients, treated with MTX or radiation therapy for breast cancer metastasis and pituitary adenoma. Neuroimaging showed brain diffuse abnormalities. Patients affected by tumors suffer from increased risk for treatment-related toxicities. Appearance or worsening of neurological signs and symptoms challenge the clinician to discriminate between CNS involvement by the tumor, toxicity of drugs, parane-oplastic disease and infections. MRI has a key role in differential diagnosis. Close interaction between the neurologist, the oncologist and the neuroradiologist leads to the optimal management of patients.",
keywords = "Mineralizing angiopathy, Neurotoxicity, Posterior reversible encephalopathy",
author = "Alessandra Erbetta and Andrea Salmaggi and Angelo Sghirlanzoni and Antonio Silvani and Paolo Potepan and Andrea Botturi and Elisa Ciceri and Bruzzone, {Maria Grazia}",
year = "2008",
month = "6",
doi = "10.1007/s10072-008-0924-3",
language = "English",
volume = "29",
pages = "131--137",
journal = "Neurological Sciences",
issn = "1590-1874",
publisher = "Springer-Verlag Italia s.r.l.",
number = "3",

}

TY - JOUR

T1 - Clinical and radiological features of brain neurotoxicity caused by antitumor and immunosuppressant treatments

AU - Erbetta, Alessandra

AU - Salmaggi, Andrea

AU - Sghirlanzoni, Angelo

AU - Silvani, Antonio

AU - Potepan, Paolo

AU - Botturi, Andrea

AU - Ciceri, Elisa

AU - Bruzzone, Maria Grazia

PY - 2008/6

Y1 - 2008/6

N2 - Antitumor and immunosuppressant treatment-related neurotoxicity can determine nonspecific clinical syndromes. Exclusion of other possible causes, among which tumor progression, appearance of paraneoplastic disease, renal or hepatic failure, diabetes or hypertension, is relevant. We report clinical and neuroradiological features in five patients with neurotoxic syndromes due to chemotherapy/radiotherapy or immunosuppression in the context of neoplastic disease/organ transplantation. Acute neurological syndrome developed in three patients after methotrexate (MTX), cyclosporine A, and L-asparaginase therapy, respectively. MRI showed posterior reversible encephalopathy in two cases and venous thrombosis with intraparenchymal hematoma in the third patient. Late onset clinical syndrome occurred in the last two patients, treated with MTX or radiation therapy for breast cancer metastasis and pituitary adenoma. Neuroimaging showed brain diffuse abnormalities. Patients affected by tumors suffer from increased risk for treatment-related toxicities. Appearance or worsening of neurological signs and symptoms challenge the clinician to discriminate between CNS involvement by the tumor, toxicity of drugs, parane-oplastic disease and infections. MRI has a key role in differential diagnosis. Close interaction between the neurologist, the oncologist and the neuroradiologist leads to the optimal management of patients.

AB - Antitumor and immunosuppressant treatment-related neurotoxicity can determine nonspecific clinical syndromes. Exclusion of other possible causes, among which tumor progression, appearance of paraneoplastic disease, renal or hepatic failure, diabetes or hypertension, is relevant. We report clinical and neuroradiological features in five patients with neurotoxic syndromes due to chemotherapy/radiotherapy or immunosuppression in the context of neoplastic disease/organ transplantation. Acute neurological syndrome developed in three patients after methotrexate (MTX), cyclosporine A, and L-asparaginase therapy, respectively. MRI showed posterior reversible encephalopathy in two cases and venous thrombosis with intraparenchymal hematoma in the third patient. Late onset clinical syndrome occurred in the last two patients, treated with MTX or radiation therapy for breast cancer metastasis and pituitary adenoma. Neuroimaging showed brain diffuse abnormalities. Patients affected by tumors suffer from increased risk for treatment-related toxicities. Appearance or worsening of neurological signs and symptoms challenge the clinician to discriminate between CNS involvement by the tumor, toxicity of drugs, parane-oplastic disease and infections. MRI has a key role in differential diagnosis. Close interaction between the neurologist, the oncologist and the neuroradiologist leads to the optimal management of patients.

KW - Mineralizing angiopathy

KW - Neurotoxicity

KW - Posterior reversible encephalopathy

UR - http://www.scopus.com/inward/record.url?scp=48949116342&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48949116342&partnerID=8YFLogxK

U2 - 10.1007/s10072-008-0924-3

DO - 10.1007/s10072-008-0924-3

M3 - Article

VL - 29

SP - 131

EP - 137

JO - Neurological Sciences

JF - Neurological Sciences

SN - 1590-1874

IS - 3

ER -